Core Insights - FTI Consulting has appointed Shelly Irvine as a Senior Managing Director in the Dispute Advisory Services practice, focusing on intellectual property matters [1][4] Company Overview - FTI Consulting, Inc. is a leading global expert firm specializing in crisis and transformation, with over 8,100 employees in 32 countries as of September 30, 2025 [5] - The company generated $3.70 billion in revenues during the fiscal year 2024 [5] Appointment Details - Shelly Irvine has nearly three decades of experience in intellectual property, having worked with clients in the US, Asia, UK, and Europe [2] - Her expertise includes litigation support, testifying roles, and consulting on strategic IP issues, particularly in life sciences, telecom, software, cloud computing, clean energy, and manufacturing [2][3] - Irvine has provided testimony in various legal settings regarding patent, copyright, trademark infringement, and trade secrets misappropriation [3] Strategic Focus - The appointment is expected to enhance FTI Consulting's ability to navigate complex international standards for IP litigation and protection [4] - Irvine's previous experience includes a role as Managing Director at Ocean Tomo, specializing in IP disputes, and nearly two decades at FTI Consulting [4]

In this articleCMCSADISWBDwatch nowMoviegoers will find a wealth of familiar franchises on the big screen this year. It may not be enough to save the box office. New entrants from popular film series dominate the movie slate in the next 12 months. The 2026 schedule features releases from Star Wars, Marvel, DC Comics, Toy Story, Super Mario Bros., Hunger Games, Scream, Scary Movie, Minions, Dune and Jumanji. Intellectual property like these established franchises has long been an important part of Hollywood, ...

SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries, today announced updates to its executive leadership team designed to strengthen execution towards the company’s long-term strategy and growth priorities. Craig Mitchell has rejoined Adeia as chief semiconductor officer, where he will lead the company’s semiconductor technology rese ...

一是创新质量持续提升。我国国内（不含港澳台）有效发明专利中，高价值发明专利同比增速比总体水 平高2.2个百分点，数量达到229.2万件。信息技术管理方法、计算机技术、医学技术等领域的有效发明 专利增速最快，人工智能专利有效量居全球前列，在量子科技、生物制造、脑机接口、第六代通讯等未 来产业布局了一批关键核心技术专利，有力促进了高水平科技自立自强。 来源：央视新闻客户端 国务院新闻办公室今天上午举行新闻发布会，国家知识产权局披露的知识产权数据，反映出以下主要特 点: 三是知识产权效益加速显现。最新数据显示，我国专利密集型产业的增加值突破18万亿元，占GDP的比 重从2020年的11.97%提升到2024年的13.38%，对经济增长的贡献度稳步提高。全球前5000个品牌中， 我国品牌价值达1.81万亿美元，位居全球第二。地理标志产品直接年产值接近1万亿元，实现五连增， 成为特色产业增收致富的"金名片"，有效助力了区域经济发展。 二是重点区域创新活跃。截至2025年底，长三角地区、京津冀地区和广东省的发明专利有效量分别为 173.4万件、91.6万件和89.9万件，合计约占国内总量的2/3；有效注册商标量合计280 ...

Core Insights - Mitsubishi Electric Corporation has been recognized as one of the Clarivate Top 100 Global Innovators for 2026, marking the 14th time the company has received this honor and ranking 17th overall this year [1] Group 1: Recognition and Awards - The award is based on patent-related data collected by Clarivate, with candidates required to have filed at least 500 patent applications since 2000 and more than 100 inventions registered as patents between 2020 and 2024 [2] - Four criteria are evaluated for selection: influence, success rate, geographic investment, and rarity [2] Group 2: Intellectual Property Strategy - Mitsubishi Electric positions intellectual property as a crucial business resource for future growth, aligning IP activities with business and R&D strategies [3] - The company launched Open Technology Bank activities in October 2021 to promote external collaboration aimed at achieving a sustainable future through leveraging IP [3]

Core Viewpoint - Amplify BlueStar Israel Technology ETF (ITEQ) offers exposure to Israel's technology ecosystem, focusing on sectors such as cybersecurity, semiconductors, communications equipment, and software and services [1] Group 1: Investment Proposition - ITEQ employs a rules-based approach that emphasizes companies linked to innovation, export markets, and intellectual-property-driven growth [1] - The portfolio typically consists of mid- and large-cap growth companies, which carry significant idiosyncratic risk [1] - Performance drivers include product-cycle strength, global IT spending, and increasing demand for security and data-centric solutions [1] Group 2: Market Challenges - Potential challenges to performance include stronger discount rates, currency fluctuations, and risk-off market conditions [1] - Geopolitical risks and country concentration are specific fund-related risks that can introduce volatility beyond typical sector dynamics [1] Group 3: Target Investors - Suitable investors include international equity allocators seeking differentiated exposure to an innovation hub and thematic investors looking to balance broader technology holdings with a distinct regional profile [1] - ITEQ can serve various portfolio roles, such as a satellite country-technology sleeve for diversification away from U.S. mega-cap tech or a tactical vehicle aligned with innovation cycles [1]

Core Insights - The PatentVest Pulse report analyzes the competitive landscape of the $1.8 trillion space economy, focusing on the intellectual property (IP) portfolios of leading companies like SpaceX, Blue Origin, and Rocket Lab [1][2] - The report emphasizes the importance of patent data in assessing the long-term value and IPO readiness of space companies, highlighting that public markets favor defensible advantages over mere narratives [2] Company Analysis - SpaceX is rumored to be pursuing a historic IPO, and the report suggests that its patent portfolio indicates a shift towards Starlink as its core business rather than just launch services [5] - Blue Origin, backed by Jeff Bezos, is establishing early IP positions in future cislunar markets, indicating a strategic focus on emerging opportunities in space [5] - Rocket Lab's growth is significantly dependent on its acquired intellectual property, showcasing the importance of strategic acquisitions in the competitive landscape [5] Industry Trends - The report notes that China and state-backed entities are dominating global launch-related patent filings, which could create competitive constraints for Western companies in the space sector [5] - The analysis of over 1,450 launch-related patent families provides insights into competitive risks and category ownership, essential for investors and stakeholders in the rapidly expanding space economy [2]

Summary of Aptar's Presentation at the 44th Annual JPMorgan Healthcare Conference Company Overview - **Company**: Aptar - **Industry**: Healthcare, specifically focusing on drug delivery systems, beauty, and closures - **Key Executives Present**: Stephan Tanda (CEO), Vanessa Kanu (CFO), Gael Touya (President, Aptar Pharma), Mary Skafidas (SVP, Investor Relations and Communications) [1] Core Business Segments - **Pharma Business**: Represents 46% of total company revenue and contributes two-thirds of EBITDA, with a growth rate of 7% [2][4] - **Beauty and Closures**: These segments are also performing well, with significant improvements noted [2][48] Financial Performance and Strategy - **Capital Allocation**: The company maintains a balanced approach, with approximately 70% of capital invested in growth and 30% returned to shareholders through dividends and share buybacks [5][44] - **Dividends**: Aptar has a history of 32 years of increasing dividends, supported by growing cash flow [5] - **Share Repurchases**: Increased activity in share buybacks, with $270 million remaining in authorization expected to be utilized [5][45] Market Dynamics and Growth Opportunities - **Total Addressable Market (TAM)**: The company is focused on large and growing markets, with Pharma leading at a 7% growth rate, Beauty at 4%, and Closures at 2% [4] - **Pipeline Growth**: Since 2019, the average weighted value of Aptar's pipeline has increased by 54%, with the number of opportunities growing by 46% [10] - **Innovative Drug Delivery**: The company is pioneering systemic nasal drug delivery, which allows for direct administration into the bloodstream, bypassing the gastrointestinal tract [11][12] Product Innovations - **Nasal Delivery Systems**: Significant advancements in drug delivery through the nasal route, including treatments for neurological disorders and chronic diseases [12][17] - **Injectables**: The injectables segment is expected to grow significantly, driven by demand for GLP-1 medications and vaccines [19][20] - **Digital Health Solutions**: Partnerships, such as with Oura, enhance patient engagement and adherence through technology [24][43] Regulatory and Competitive Position - **Regulatory Expertise**: Aptar's deep regulatory knowledge is a competitive advantage, allowing for successful navigation of the drug approval process [6][7] - **Intellectual Property**: The company emphasizes the importance of its IP portfolio, which includes patents and trade secrets, as a core component of its business strategy [28][29] Challenges and Market Adjustments - **Narcan Market Dynamics**: The company anticipates a normalization period following a surge in Narcan sales, with a projected $65 million headwind expected in the first half of 2026 due to inventory adjustments [30][33] - **Supply Chain Strategy**: Aptar's four-region supply chain strategy positions it well to meet market demands amid geopolitical challenges [20] Conclusion - **Overall Outlook**: Aptar is well-positioned for growth with a strong pipeline, innovative drug delivery solutions, and a commitment to sustainability and patient-centric approaches [24][42]

Core Insights - cbdMD, Inc has completed the acquisition of substantially all assets of Bluebird Botanicals, enhancing its revenue base and long-term growth strategy [1][3] Acquisition Details - The acquisition was executed through an asset purchase involving an initial share issuance and earnout shares, with specific terms detailed in a Form 8-K filed with the SEC [2] - The all-equity purchase price is expected to strengthen cbdMD's balance sheet and highlight the strategic alignment between the two brands [4] Brand Synergy and Consumer Focus - The merger combines two brands that prioritize quality and consumer experience, with Bluebird Botanicals having a loyal customer base and backing from Juggernaut Capital Partners [3] - The partnership aims to enhance wellness solutions and deliver greater value to consumers across the nation [4] Operational Efficiencies - Management anticipates operational efficiencies through a consolidated supply chain, manufacturing, and shared services, contingent on successful integration [4] - The acquisition is expected to broaden product offerings and create cross-brand distribution opportunities, accelerating revenue growth in both direct-to-consumer and retail channels [4] Intellectual Property and Growth Potential - The transaction adds a differentiated portfolio of intellectual property, including patented-process technologies and regulatory compliance documentation, which may enhance strategic flexibility as regulations evolve [5] - The expanded IP base could provide value as new regulations take effect, potentially leading to clearer pathways for innovation [5] Financial Outlook - The acquisition is projected to enhance cbdMD's revenue foundation, support the goal of achieving positive EBITDA and net income, and bolster the company's ability to innovate responsibly [6]

Strategic Partnership - Disney entered into a billion-dollar deal with OpenAI [1] - The deal signifies a shift in Disney's approach to intellectual property, moving from safeguarding to collaboration [1] Potential Gains - The partnership aims to explore potential benefits and opportunities arising from integrating OpenAI's technology [1] Timing - The timing of the deal suggests a strategic decision to leverage AI advancements now [1]